Bimatoprost With Timolol MaleateGanfort
Recommended OphthalmologyRestrictedLater-line line
Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension who are not adequately controlled with other treatments.
1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2009 Recommended Anti-glaucoma
Access path
- TGA registered · Ganfort
TGA label narrower than the PBS population
- Mar 2009Recommended · restricted
vs bimatoprost 0.03% and timolol maleate 0.5% eye drops given…
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
Comparative effectiveness
For PBAC’s view, see Recommendation and Reasons. 10. Economic Analysis The submission presented a cost minimisation analysis. According to Study 026T, the equi- effective doses were estimated as bimatoprost with timolol one drop instilled once daily and concomitant bimatoprost 0.3mg/mL one drop instilled once daily plus timolol maleate 5mg/mL one drop instilled twice daily. 11.PSD · Mar 2009
The submission argued that because the patients who received bimatoprost with timolol would have been treated with two prostaglandin analogue fixed combinations currently listed on the PBS (latanoprost with timolol and travoprost with timolol), there would be no net increase in cost to the PBS/RPBS should bimatoprost with timolol be listed. 12.PSD · Mar 2009
Cost-effectiveness
Cost-minimisation analysis performed; no ICER calculated
The PBAC recommended the listing of bimatoprost with timolol maleate on the PBS and also for inclusion in the Optometrical Schedule, in accordance with the combination guidelines, on a cost-minimisation basis compared with its constituent components, bimatoprost 0.03% and timolol maleate 0.5% eye drops given concomitantly. PBAC · 2009
Cost-effectiveness accepted
Decision context
Populationpatients with open-angle glaucoma or ocular hypertension who are not adequately controlled with other treatments
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2009 | Recommended · restricted | bimatoprost 0.03% and timolol maleate 0.5% eye drops given concomitantly | — | RCT, Single-arm, Registry · OS | PFS | DFS | ORR | QoL | Surrogate |
Similar precedents
Travoprost With Timolol Maleate, Eye Drops83%Betaxolol, Bimatoprost, Bimatoprost + Timolol, Brimonidine, Brimonidine + Timolol, Brinzolamide, Brinzolamide + Timolol, Dorzolamide, Dorzolamide + Timolol, Latanoprost, Latanoprost + Timolol, Pilocarpine, Timolol, Travoprost, Timolol + Travoprost81%Latanoprost With Timolol Maleate81%Dorzolamide Hydrochloride With Timolol Maleate, Eye Drops79%Brinzolamide/Brimonidine Tartrate78%Bimatoprost77%Travoprost With Timolol Maleate76%Dorzolamide With Timolol75%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled with other treatments (later-line), narrowing the TGA's broader open-angle glaucoma/ocular hypertension population.